-
Company Insights
Innovation and Patenting activity of Adani Ports and Special Economic Zone Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Adani Ports and Special Economic Zone Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request....
-
Company Insights
Innovation and Patenting activity of Jiangxi Special Electric Motor Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Jiangxi Special Electric Motor Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
Likelihood of Approval Analysis for Leber Congenital Amaurosis (LCA)
Overview How likely is it that the drugs in Leber Congenital Amaurosis (LCA) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leber Congenital Amaurosis (LCA) Overview Leber congenital amaurosis (LCA) is...
-
Product Insights
Likelihood of Approval Analysis for Dermatological Disorders
Overview How likely is it that the drugs in Dermatological Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dermatological Disorders Overview Dermatological disorders are diseases or conditions that affect the...
-
Product Insights
Likelihood of Approval Analysis for Eosinophilic Esophagitis
Overview How likely is it that the drugs in Eosinophilic Esophagitis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eosinophilic Esophagitis Overview Eosinophilic esophagitis is disease characterized by the presence of...
-
Product Insights
Likelihood of Approval Analysis for Neuroendocrine Cancer
Overview How likely is it that the drugs in Neuroendocrine Cancer will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neuroendocrine Cancer Overview A neuroendocrine cancer, often referred as a neuroendocrine tumor...
-
Product Insights
Likelihood of Approval Analysis for Macular Edema
Overview How likely is it that the drugs in Macular Edema will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Macular Edema Overview Macular edema is swelling or fluid retention in a...
-
Product Insights
Likelihood of Approval Analysis for Nociceptive Pain
Overview How likely is it that the drugs in Nociceptive Pain will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nociceptive Pain Overview Nociceptive pain is a type of pain caused by...
-
Sector Analysis
NewGeneral Hospital Supplies Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
General Hospital Supplies Market Report Overview The general hospital supplies market size was $12.7 billion in 2023. Factors such as the solid awareness about ensuring medical facilities will drive the market growth at a CAGR of more than 2% from 2023 to 2033. General hospital supplies support patient care and safety irrespective of the reason they might be visiting the hospital. General hospital supplies form the equipment base of all healthcare facilities in any country. For any kind of treatment...
-
Sector Analysis
NewNigeria Upstream (Oil and Gas) Fiscal and Regulatory Guide, 2024
The upstream fiscal and regulatory outlook of Nigeria underwent a comprehensive reform with the Petroleum Industry Act (PIA) of 2021. Nigeria has implemented different contractual regimes for oil exploration and production, including Production Sharing Agreements (PSAs), Joint Ventures and concessions in the form of Sole Risk agreements, with special conditions for marginal fields. In the latest reform, the Nigerian National Petroleum Corporation (NNPC) is replaced with a limited liability company, NNPC Ltd, and is now enabled for joint venture arrangements,...